Last reviewed · How we verify

NCT03716999

Starlight Therapy in Palliative Care

Not yet recruiting Last updated 23 August 2024
What this trial tests

trial testing Starlight Therapy in Symptom Management in 100 participants. Not yet recruiting.

Timeline
15 December 2026
Primary endpoint
30 November 2027
30 November 2027

Quick facts

Lead sponsorNova Scotia Health Authority
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment100
Start date15 December 2026
Primary completion30 November 2027
Estimated completion30 November 2027
Sites1 location across Canada

Drugs / interventions tested

Conditions studied

Sponsor

Nova Scotia Health Authority — full company profile →

Who can join

Eligibility, any sex, with Symptom Management. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Starlight Therapy™ has been shown to help alleviate end-of-life symptoms in Palliative Care patients and reduce the need for PRN or "as needed" medications. This study will investigate the efficacy of this intervention on the symptom of anxiety using a mixed-method analysis. The primary investigator hypothesizes that any anti-anxiolytic effects could be caused by the Intrinsically Photosensitive Retinal Ganglion Cell neural pathway to the amygdala.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Symptom Management

Currently open trials in the same condition.

Other Nova Scotia Health Authority trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03716999.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing